PALI

Nasdaq

PALISADE BIO, INC.

Latest disclosureOctober 5, 2026

Insider score Why 20?: 20/ 100
Qualifying buys · 30d: $28.8K

8 purchases · 2 sales

Price by TradingView

Insider transactions 29

Limited filing history

Filters

Last 30 daysInsiders bought $28.8K · 1 buyer, led by Donald Allen Williams (Director) with $28.8K. No qualifying insider sales.

Sale disclosed

Mitchell Lawrence Jones

Chief Medical Officer

Common Stock

Reported value: $106.54K
Reported price: $2.0535 / share

Sale disclosed

John David Finley

CEO, CFO

Common Stock

Reported value: $303.34K
Reported price: $2.0664 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Chief Medical Officer	Common StockSale	51,880$2.05 / share	$106.54K	Jul 7Filed Jul 8 · 1d later	SEC filing
CEO, CFO	Common StockSale	146,798$2.07 / share	$303.34K	Jul 7Filed Jul 8 · 1d later	SEC filing

Congress transactions 0

All Congress filings

No disclosed congressional trades for PALI in the imported filings.

This reflects the filings imported so far, not a complete trading history.

Why this buying score?

Qualifying common-equity purchase value

$91,346 of common-equity purchase value after transaction-age decay across 180 days.

+6 pts

Distinct buying groups

2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+9 pts

Repeated purchases

A reporting-owner group bought on at least two distinct dates within the cluster window.

+5 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001357459
Latest public acceptance: Oct 5, 2026, 09:20 PM UTC
Score calculated: Oct 8, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Chief Medical Officer

Common StockSale

51,880$2.05 / share

$106.54K

Jul 7Filed Jul 8 · 1d later

SEC filing

CEO, CFO

Common StockSale

146,798$2.07 / share

$303.34K

Jul 7Filed Jul 8 · 1d later

SEC filing

Why this buying score?

Qualifying common-equity purchase value

$91,346 of common-equity purchase value after transaction-age decay across 180 days.

+6 pts

Distinct buying groups

2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+9 pts

Repeated purchases

A reporting-owner group bought on at least two distinct dates within the cluster window.

+5 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001357459
Latest public acceptance: Oct 5, 2026, 09:20 PM UTC
Score calculated: Oct 8, 2026, 12:06 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.